



(51) International Patent Classification:

C07D 261/14 (2006.01) *C07D 417/12* (2006.01)
C07D 413/12 (2006.01) *C07D 417/14* (2006.01)
C07D 413/14 (2006.01) *A61K 31/42* (2006.01)
C07D 417/06 (2006.01) *A61P 29/00* (2006.01)

(21) International Application Number:

PCT/US2010/037697

(22) International Filing Date:

8 June 2010 (08.06.2010)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/186,920 15 June 2009 (15.06.2009) US

(71) Applicant (for all designated States except US):

BOEHRINGER INGELHEIM INTERNATIONAL GMBH [DE/DE]; Binger Strasse 173, 55216 Ingelheim (DE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **BARTOLOZZI,**

Alessandra [IT/US]; Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, P.O. Box 368, Ridgefield, CT 06877-0368 (US). **HICKEY, Eugene, Richard** [US/US]; Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, P.O. Box 368, Ridgefield, CT 06877-0368 (US). **RIETHER, Doris** [AT/US]; Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, P.O. Box 368, Ridgefield, CT 06877-0368 (US). **WU, Lifan** [CN/US]; Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, P.O. Box 368, Ridgefield, CT 06877-0368 (US). **ZINDELL, Renee** [US/US]; Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, P.O. Box 368, Ridgefield, CT 06877-0368 (US). **BLUMIRE, Nigel** [GB/GB]; 114 Mil-

ton Park, Abingdon, Oxfordshire OX14 4SA (GB). **ERMANN, Monika** [AT/GB]; 114 Milton Park, Abingdon, Oxfordshire OX14 4SA (GB). **GLENN, Edward, Thomas** [GB/GB]; 114 Milton Park, Abingdon, Oxfordshire OX14 4SA (GB). **KHOR, Someina** [MY/GB]; 114 Milton Park, Abingdon, Oxfordshire OX14 4SA (GB). **ZAWADZKI, Przemyslaw** [PL/PL]; Selvita, Ul. Ostatnia 1C, PL-31-444 Krakow (PL).

(74) Agents: **MORRIS, Michael, P.** et al.; Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, P.O. Box 368, Ridgefield, CT 06877-0368 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.


(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

[Continued on next page]

(54) Title: COMPOUNDS WHICH SELECTIVELY MODULATE THE CB2 RECEPTOR



(57) Abstract: Compounds of formula (I) are disclosed. Compounds according to the invention bind to and are agonists, antagonists or inverse agonists of the CB2 receptor, and are useful for treating inflammation. Those compounds which are agonists are additionally useful for treating pain.



— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

(88) Date of publication of the international search report:
1 September 2011